Prognostic impact of fascin-1 (FSCN1) in epithelial ovarian cancer

Anticancer Research

Volumn 33, Issue 2, 2013, Pages 371-378

  Hanker, Lars C ^a   Karn, Thomas ^a   Holtrich, Uwe ^a   Graeser, Monika ^b   Becker, Sven ^a   Reinhard, Joscha ^a   Ruckhaberle, Eugen ^a   Gevensleben, Heidrun ^c   Rody, Achim ^d  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Expression; Fascin 1; Ovarian cancer; Prognosis immunohistochemistry.

Indexed keywords

FASCIN;

ADULT; AGED; APPENDECTOMY; ARTICLE; CANCER PROGNOSIS; CANCER SURGERY; DISEASE SEVERITY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; OMENTECTOMY; OVARY CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SALPINGOOOPHORECTOMY; SURVIVAL RATE; TUMOR CELL; TUMOR VOLUME;

CARRIER PROTEINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MICROFILAMENT PROTEINS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TUMOR MARKERS, BIOLOGICAL;

EID: 84875880160     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin 62(1): 10-29, 2012.
2. Vaughan S, Coward JI, Bast RC Jr., Berchuck A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R, Etemadmoghadam D, Friedlander M, Gabra H, Kaye SB, Lord CJ, Lengyel E, Levine DA, McNeish IA, Menon U, Mills GB, Nephew KP, Oza AM, Sood AK, Stronach EA, Walczak H, Bowtell DD and Balkwill FR: Rethinking ovarian cancer: Recommendations for improving. Nat Rev Cancer 11(10): 719-725, 2011.
3. Hennessy BT, Coleman RL and Markman M: Ovarian cancer. Lancet 374(9698): 1371-1382, 2009.
4. Buys SS, Partridge E, Black A, Johnson CC, Lamerato L, Isaacs C, Reding DJ, Greenlee RT, Yokochi LA, Kessel B, Crawford ED, Church TR, Andriole GL, Weissfeld JL, Fouad MN, Chia D, O'Brien B, Ragard LR, Clapp JD, Rathmell JM, Riley TL, Hartge P, Pinsky PF, Zhu CS, Izmirlian G, Kramer BS, Miller AB, Xu JL, Prorok PC, Gohagan JK and Berg CD for the PLCO Project Team: Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA 305(22): 2295-2303, 2011.
5. Landen CN Jr., Birrer MJ and Sood AK: Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol 26(6): 995-1005, 2008.
6. Cho KR and Shih IM: Ovarian cancer. Annu Rev Pathol 4: 287-313, 2009.
7. du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I and Pfisterer J: Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer 115(6): 1234-1244, 2009.
8. Lengyel E: Ovarian cancer development and metastasis. Am J Pathol 177(3): 1053-1064, 2010.
9. Cavallaro U and Christofori G: Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat Rev Cancer 4(2): 118-132, 2004.
10. Huber MA, Kraut N and Beug H: Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol 17(5): 548-558, 2005.
11. Kalluri R and Weinberg RA: The basics of epithelial-mesenchymal transition. J Clin Invest 119(6): 1420-1428, 2009.
12. Adams JC: Fascin protrusions in cell interactions. Trends Cardiovasc Med 14(6): 221-226, 2004.
13. Edwards RA and Bryan J: Fascins, a family of actin-bundling proteins. Cell Motil Cytoskeleton 32(1): 1-9, 1995.
14. Al-Alwan M, Olabi S, Ghebeh H, Barhoush E, Tulbah A, Al-Tweigeri T, Ajarim D and Adra C: Fascin is a key regulator of breast cancer invasion that acts via the modification of metastasis-associated molecules. PLoS One 6(11): e27339, 2011.
15. Duh FM, Latif F, Weng Y, Geil L, Modi W, Stackhouse T, Matsumura F, Duan DR, Linehan WM, Lerman MI and Gnarra JR: cDNA cloning and expression of the human homolog of the sea urchin fascin and Drosophila singed genes which encodes an actin-bundling protein. DNA Cell Biol 13(8): 821-827, 1994.
16. Mosialos G, Birkenbach M, Ayehunie S, Matsumura F, Pinkus GS, Kieff E and Langhoff E: Circulating human dendritic cells differentially express high levels of a 55-kDa actin-bundling protein. Am J Pathol 148(2): 593-600, 1996.
17. Mosialos G, Yamashiro S, Baughman RW, Matsudaira P, Vara L, Matsumura F, Kieff E and Birkenbach M: Epstein-Barr virus infection induces expression in B lymphocytes of a novel gene encoding an evolutionarily conserved 55-kilo Dalton actinbundling protein. J Virol 68(11): 7320-7328, 1994
18. Pinkus GS, Pinkus JL, Langhoff E, Matsumura F, Yamashiro S, Mosialos G and Said JW: Fascin, a sensitive new marker for Reed-Sternberg cells of hodgkin's disease. Evidence for a dendritic or B-cell derivation? Am J Pathol 150(2): 543-562, 1997.
19. Yoder BJ, Tso E, Skacel M, Pettay J, Tarr S, Budd T, Tubbs RR, Adams JC and Hicks DG: The expression of fascin, an actinbundling motility protein, correlates with hormone receptornegative breast cancer and a more aggressive clinical course. Clin Cancer Res 11: 186-192, 2005.
20. Jawhari AU, Buda A, Jenkins M, Shehzad K, Sarraf C, Noda M, Farthing MJ, Pignatelli M and Adams JC: Fascin, an actinbundling protein, modulates colonic epithelial cell invasiveness and differentiation in vitro. Am J Pathol 162: 69-80, 2003.
21. Hashimoto Y, Shimada Y, Kawamura J, Yamasaki S and Imamura M: The prognostic relevance of fascin expression in human gastric carcinoma. Oncology 67: 262-270, 2004.
22. Hashimoto Y, Ito T, Inoue H, Okumura T, Tanaka E, Tsunoda S, Higashiyama M, Watanabe G, Imamura M and Shimada Y: Prognostic significance of fascin overexpression in human esophageal squamous cell carcinoma. Clin Cancer Res 11: 2597-2605, 2005.
23. Zhao JB, Zhou YG, Zhang ZP, Tian F, Ma N, Liu TG, Gu ZP and Wang YJ: Up-regulated fascin 1 in non-small cell lung cancer promotes the migration and invasiveness, but not proliferation. Cancer Lett 290: 238-247, 2010.
24. Hu W, McCrea PD, Deavers M, Kavanagh JJ, Kudelka AP and Verschraegen CF: Increased expression of fascin, motility associated protein, in cultures derived from ovarian cancer and in borderline and carcinomatous ovarian tumors. Clin Exp Metastasis 18: 83-88, 2000.
25. Lee KR, Tavassoli FA and Prat J: Tumours of the ovary and peritoneum. In: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Tavassoli FA, Devilee P (eds.). Lyon, IARC Press, pp. 113-145, 2003.
26. Remmele W and Stegner HE: Pathologe 8(3): 138-140, 1987.
27. Tao YS, Edwards RA, Tubb B, Wang S, Bryan J and McCrea PD: β-Catenin associates with the actin-bundling protein fascin in a noncadherin complex. J Cell Biol 134(5): 1271-1281, 1996.
28. Lin CK, Chao TK, Yu CP, Yu MH and Jin JS: The expression of six biomarkers in the four most common ovarian cancers: Correlation with clinicopathological parameters. APMIS 117(3): 162-175, 2009.
29. Kabukcuoglu S, Oner U, Ozalp SS, Bildirici K, Yalcin OT and Colak E: The role of actin-bundling protein fascin in the progression of ovarian neoplasms. Eur J Gynaecol Oncol 27(2): 171-176, 2006.
30. Wen YH, Yee H, Goswami S and Shukla PS: Fascin expression in serous tumors of ovary correlates with aggressiveness of malignancy. Int J Gynecol Pathol 28(2): 187-192, 2009.
31. Daponte A, Kostopoulou E, Papandreou CN, Daliani DD, Minas M, Koukoulis G and Messinis IE: Prognostic significance of fascin expression in advanced poorly differentiated serous ovarian cancer. Anticancer Res 28(3B): 1905-1910, 2008.